Literature DB >> 30705854

Neoadjuvant immunotherapy in non-small cell lung cancer: the sooner the better?

Jose Luis Perez-Gracia1,2,3, Miguel F Sanmamed1,2, Ignacio Melero2,3,4.   

Abstract

Entities:  

Year:  2018        PMID： 30705854      PMCID： PMC6328681          DOI： 10.21037/tlcr.2018.10.12

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  10 in total

Review 1.  Strategies to design clinical studies to identify predictive biomarkers in cancer research.

Authors:  Jose Luis Perez-Gracia; Miguel F Sanmamed; Ana Bosch; Ana Patiño-Garcia; Kurt A Schalper; Victor Segura; Joaquim Bellmunt; Josep Tabernero; Christopher J Sweeney; Toni K Choueiri; Miguel Martín; Juan Pablo Fusco; Maria Esperanza Rodriguez-Ruiz; Alfonso Calvo; Celia Prior; Luis Paz-Ares; Ruben Pio; Enrique Gonzalez-Billalabeitia; Alvaro Gonzalez Hernandez; David Páez; Jose María Piulats; Alfonso Gurpide; Mapi Andueza; Guillermo de Velasco; Roberto Pazo; Enrique Grande; Pilar Nicolas; Francisco Abad-Santos; Jesus Garcia-Donas; Daniel Castellano; María J Pajares; Cristina Suarez; Ramon Colomer; Luis M Montuenga; Ignacio Melero
Journal:  Cancer Treat Rev       Date:  2016-12-30       Impact factor: 12.111

2.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

3.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Cyril Konto; Axel Hoos; Veerle de Pril; Ravichandra Karra Gurunath; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  Lancet Oncol       Date:  2015-03-31       Impact factor: 41.316

4.  Making the Most of Cancer Surgery with Neoadjuvant Immunotherapy.

Authors:  Ignacio Melero; Pedro Berraondo; María E Rodríguez-Ruiz; José L Pérez-Gracia
Journal:  Cancer Discov       Date:  2016-12       Impact factor: 39.397

5.  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Authors:  T R Cottrell; E D Thompson; P M Forde; J E Stein; A S Duffield; V Anagnostou; N Rekhtman; R A Anders; J D Cuda; P B Illei; E Gabrielson; F B Askin; N Niknafs; K N Smith; M J Velez; J L Sauter; J M Isbell; D R Jones; R J Battafarano; S C Yang; L Danilova; J D Wolchok; S L Topalian; V E Velculescu; D M Pardoll; J R Brahmer; M D Hellmann; J E Chaft; A Cimino-Mathews; J M Taube
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

6.  Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Authors:  Jing Liu; Stephen J Blake; Michelle C R Yong; Heidi Harjunpää; Shin Foong Ngiow; Kazuyoshi Takeda; Arabella Young; Jake S O'Donnell; Stacey Allen; Mark J Smyth; Michele W L Teng
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

7.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

8.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

9.  Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.

Authors:  Xiaolin Liu-Jarin; Mark B Stoopler; Haralambos Raftopoulos; Mark Ginsburg; Lyall Gorenstein; Alain C Borczuk
Journal:  Mod Pathol       Date:  2003-11       Impact factor: 7.842

10.  A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.

Authors:  Yuki Yamane; Genichiro Ishii; Koichi Goto; Motohiro Kojima; Masayuki Nakao; Yoshihisa Shimada; Yutaka Nishiwaki; Kanji Nagai; Hirotsugu Kohrogi; Atsushi Ochiai
Journal:  J Thorac Oncol       Date:  2010-01       Impact factor: 15.609
  10 in total
  3 in total

1.  [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].

Authors:  Shijie Zhou; Xuefeng Hao; Daping Yu; Shuku Liu; Xiaoqing Cao; Chongyu Su; Xiaoyun Song; Ning Xiao; Yunsong Li; Wei Yang; Dan Zhao; Jinghui Wang; Zhidong Liu; Shaofa Xu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-24

2.  Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report.

Authors:  Yu Tian; Jia Huang; Chongwu Li; Long Jiang; Hao Lin; Peiji Lu; Qingquan Luo; Guocai Yang
Journal:  Ann Transl Med       Date:  2020-06

Review 3.  [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].

Authors:  Shuaibo Wang; Yousheng Mao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.